{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:03:04Z","timestamp":1771016584621,"version":"3.50.1"},"reference-count":11,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,3,1]]},"abstract":"<jats:p>Objectives.\u2003Life-threatening arrhythmias and prolonged QT interval have been reported in adults and children using cisapride, a medication structurally similar to procainamide. Premature infants have reduced activity of cytochrome p-450, the system responsible for metabolism of cisapride, which could lead to QT prolongation. Therefore, we prospectively studied premature infants and children receiving cisapride to analyze the effect of prolonged cisapride therapy on QT interval.<\/jats:p>\n               <jats:p>Design.\u2003Premature infants in a neonatal intensive care unit and children seen at a pediatric gastroenterology clinic in a tertiary care hospital had electrocardiography-analyzed and -corrected QT interval measured before cisapride (0.8\/mg\/kg per day) therapy, and again after 1 month of therapy. If baseline electrocardiography was not performed initially, it was obtained after cessation of therapy.<\/jats:p>\n               <jats:p>Results.\u2003A total of 30 children participated in the study. Mean corrected QT interval was similar at baseline and at 1 month after therapy. Significant QT prolongation was not found, and no adverse effects were recorded.<\/jats:p>\n               <jats:p>Conclusions.\u2003Corrected QT interval during prolonged cisapride therapy at 0.8 mg\/kg per day appears to be similar for premature infants and children. An inherent trend toward QT prolongation was not detected in either group. In the absence of other risk factors that alter cisapride metabolism or predispose to arrhythmia, cisapride may be safe for use in premature infants as well as in children. Additional studies are needed to confirm these data.<\/jats:p>","DOI":"10.1542\/peds.101.3.e9","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:44:32Z","timestamp":1092440672000},"page":"e9-e9","source":"Crossref","is-referenced-by-count":24,"title":["QT Interval in Children and Infants Receiving Cisapride"],"prefix":"10.1542","volume":"101","author":[{"given":"Arie","family":"Levine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Fogelman","sequence":"additional","affiliation":[{"name":"From the Division of Gastroenterology and Nutrition, theDivision of Cardiology, and the"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Sirota","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, Schneider Children's Medical Center of Israel, Tel Aviv University Sackler School of Medicine, Petah Tikva, Israel."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zili","family":"Zangen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raanan","family":"Shamir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Dinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[1998,3,1]]},"reference":[{"key":"2021121000255749400_B1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJM199607253350416","article-title":"Cisapride and fatal arrhythmia.","volume":"355","author":"Wysowski","year":"1996","journal-title":"N Engl J Med."},{"key":"2021121000255749400_B2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00003246-199607000-00035","article-title":"Cisapride-induced dysrrhythmia in a pediatric patient receiving extracorporeal life support.","volume":"24","author":"Pettignano","year":"1996","journal-title":"Crit Care Med."},{"key":"2021121000255749400_B3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0022-3476(96)70409-2","article-title":"Cisapride-induced long QT interval.","volume":"128","author":"Lewin","year":"1996","journal-title":"J Pediatr."},{"key":"2021121000255749400_B4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00005176-199611000-00003","article-title":"Report from the NASPGN Therapeutics Subcommittee: Cisapride and the attack of the P-450s.","volume":"23","author":"Shulman","year":"1996","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2021121000255749400_B5","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0022-3476(74)80465-8","article-title":"Hepatic microsomal drug oxidation and electron transport in newborn infants.","volume":"85","author":"Aranda","year":"1974","journal-title":"J Pediatr."},{"key":"2021121000255749400_B6","first-page":"353","article-title":"An analysis of the time relations of the electrocardiogram.","volume":"7","author":"Bazzett","year":"1920","journal-title":"Heart."},{"key":"2021121000255749400_B7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/bmj.305.6856.748-a","article-title":"Tachycardia during cisapride treatment.","volume":"305","author":"Olsson","year":"1992","journal-title":"Br Med J."},{"key":"2021121000255749400_B8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/0002-9149(81)90264-2","article-title":"Procainamide-induced polymorphous ventricular tachycardia.","volume":"47","author":"Strasberg","year":"1981","journal-title":"Am J Cardiol."},{"key":"2021121000255749400_B9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1476-5381.1990.tb14108.x","article-title":"A 5-hydroxytryptamine receptor in human atrium.","volume":"100","author":"Kaumann","year":"1990","journal-title":"Br J Pharmacol."},{"key":"2021121000255749400_B10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0165-6147(94)90058-2","article-title":"Do human atrial 5-HT4 receptors mediate arrhythmias?","volume":"15","author":"Kaumann","year":"1994","journal-title":"Trends Pharmacol Sci."},{"key":"2021121000255749400_B11","first-page":"631","article-title":"Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility.","volume":"47","author":"Briejer","year":"1995","journal-title":"Pharmacol Rev."}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/101\/3\/e9\/828179\/e9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/101\/3\/e9\/828179\/e9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T07:09:01Z","timestamp":1639120141000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/101\/3\/e9\/61933\/QT-Interval-in-Children-and-Infants-Receiving"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,3,1]]},"references-count":11,"journal-issue":{"issue":"3","published-online":{"date-parts":[[1998,3,1]]},"published-print":{"date-parts":[[1998,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.101.3.e9","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[1998,3,1]]}}}